RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.

Proxy Form For Use
At The 2025 First Extraordinary General Meeting

Announcements and Notices - [Notice of EGM/SGM / Closure of Books or Change of Book Closure Period]

Notice Of 2025 First Extraordinary General Meeting

Circulars - [Re-election or Appointment of Director subject to Shareholders' Approval]

Proposed Appointment Of
New Independent Non-Executive Director
And
Notice Of 2025 First Extraordinary General Meeting

Announcements and Notices - [Change in Directors or of Important Executive Functions or Responsibilities]

Proposed Appointment Of
New Independent Non-Executive Director

Announcements and Notices - [Closure of Books or Change of Book Closure Period]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Remegen (9995 HK)

Proxy Form For Use At The 2025 First Extraordinary General Meeting

Notice Of 2025 First Extraordinary General Meeting

Proposed Appointment Of New Independent Non-Executive Director And Notice Of 2025 First Extraordinary General Meeting

Proposed Appointment Of New Independent Non-Executive Director

Closure Of Register Of Members For 2025 First Extraordinary General Meeting

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)